Featured Articles

Novartis announced that it has successfully completed the acquisition of Tourmaline Bio, Inc., making the biotechnology company an indirect wholly owned subsidiary of Novartis.…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of WINREVAIR™ (sotatercept-csrk) for the…
Read More...

GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide…
Read More...

Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

Novo Nordisk and Omeros Corporation have entered into a definitive agreement granting Novo Nordisk exclusive global rights to zaltenibart (formerly OMS906), a clinical-stage antibody…
Read More...

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million, aiming to expand its portfolio of treatments for…
Read More...

Pfizer Inc. announced positive topline results from its Phase 3 HER2CLIMB-05 trial, marking a potential breakthrough in first-line treatment for patients with HER2-positive (HER2+)…
Read More...

Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for its new oral therapy, JASCAYD (nerandomilast), for the treatment of idiopathic pulmonary…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab-rwlc) as the first adjuvant immunotherapy for adult patients with cutaneous…
Read More...

Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...

Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.'s…
Read More...

AstraZeneca and Daiichi Sankyo announced positive interim results from the DESTINY-Breast05 Phase III trial, reinforcing Enhertu’s (trastuzumab deruxtecan) potential as a foundational…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved its biologic therapy TREMFYA® (guselkumab) for use in children aged six years and older…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), a new oral treatment from Eli Lilly and Company, for adults with estrogen…
Read More...

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Enhertu…
Read More...

Sanofi Ventures has received an additional $625 million multi-year capital commitment from its parent company, Sanofi, increasing its total assets under management to over $1.4 billion.…
Read More...

Moderna, Inc. has officially opened its Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK. This new facility will…
Read More...